Atlas Trials

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Clinical trial NCT04799847 · UNKNOWN

Trial details

NCT number
NCT04799847
Sponsor
LintonPharm Co.,Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2021-11-23
Primary completion
2024-11-30
Enrollment
161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.